A cannabinoid-based
biopharmaceutical company.
We are focused on drug discovery & personalized medicine derived from plant-based therapeutics and combination therapies.
The new frontier between medicine and botany.
The new frontier between medicine and botany.
OUR PIPELINE
Â
MEET TARGETED PHARMACEUTICALS
​
Our goal is to bring precision medicine and real science to the cannabis industry by linking the molecular structure of humans to cannabinoid compounds.
​
Technology and data are at the core of what we do. We are very much a data-driven technology company focused on using data for personalized cannabinoid care.
Â
TOP TEAM & ADVISORS FROM
Â
TOP TEAM & ADVISORS FROM
George Mason University
National Cancer Institute
Harvard University
Worcester Polytechnic Institute
McLean Hospital
Food & Drug Adminstration
OUR TEAM
ALAN CARPINO, CO-FOUNDER
Mr. Carpino has been a senior executive in the pharmaceutical and bioscience space and has worked for Thermo Fisher Scientific, Millennium Pharmaceuticals, and Fluidigm. He is a graduate of Mt Ida College and Florida Southern College.
JARET CHRISTOPHER, CHAIRMAN
Jaret is a serial entrepreneur with 20+ experience building technology and data-driven companies. He is the founder of Cannabis Venture Partners, Sprout, MortgageCEO, and TrueAdvantage. Jaret holds a BS in Engineering from Worcester Polytechnic Institute.
DR. LANCE LIOTTA, PhD, MD, CHIEF MEDICAL OFFICER
Dr. Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine at George Mason University. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology for the National Cancer Institute, and the Deputy Director of National Institute of Health, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program. Dr. Liotta has more than 100 issued or allowed patents and more than 690 publications. He is Board Certified in Anatomic Pathology and is Medical Director of the GMU CAP/CLIA certified clinical proteomics Lab. He is a founder of Theranostics Health and Ceres Nanosciences.
DR. T. WILSON WOO, MD, SCIENTIFIC ADVISOR
Dr. Woo is the Medical Director at McLean Hospital for the Harvard University Brain Tissue & Resource Center and the Laboratory of Cellular Neuropathology. Dr. Woo’s research interest is in defining the nature of cortical circuitry disturbances in schizophrenia and other psychotic disorders, and in understanding the developmental neurobiological pathways that lead to these disturbances.
DR. PAMELA WEATHERS, PhD, SCIENTIFIC ADVISOR, BOTANY
Dr. Weathers is an internationally recognized expert on Artemisia annua and artemisinin, having worked with the plant and its phytochemicals including the antimalarial drug, artemisinin. She is a Fellow of AAAS and SIVB, won many awards, given many national and international presentations, reviews manuscripts for many journals and proposals for many national and international funding agencies. She is an Associate Editor for two journals. Her lab was the first to genetically transform A. annua. She spearheaded the edible A. annua concept for treating malaria and other diseases and has led all research to date on the project to establish proof-of-concept.
Â
GET
IN TOUCH
Targeted Pharmaceuticals is a cannabinoid-based drug discovery company.
Â
